Cepacol Antibacterial Mouthwash Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cepacol Antibacterial Mouthwash Availability in 2026

If your patients have been reporting difficulty finding Cepacol Antibacterial Multi-Protection Mouthwash, their experience reflects a broader pattern of inconsistent availability that has emerged over the past several years. This briefing provides clinicians, dental professionals, and prescribers with a comprehensive overview of the current situation, its implications for patient care, and actionable steps to ensure continuity of oral health treatment.

Cepacol Antibacterial Mouthwash contains Cetylpyridinium Chloride (CPC) 0.05% and is classified as an OTC antigingivitis/antiplaque oral rinse. It is manufactured by RB Health (US) LLC and has long been recognized as the #1 mouthwash brand in hospital settings. Many providers recommend it specifically for its hospital-grade reputation and established clinical profile.

Timeline of Availability Issues

The availability challenges with Cepacol Antibacterial Mouthwash have developed incrementally:

• 2020–2022: Broader supply chain disruptions across consumer health products affected multiple brands, including Cepacol. Intermittent availability began at some retail locations.
• 2022–2023: The 32 fl oz Cepacol Antibacterial Mouthwash Mint formulation was discontinued by the previous manufacturer (Combe). This eliminated a popular product size from the market.
• 2023–2024: RB Health (US) LLC continued production of the 24 fl oz Multi-Protection formula, but retail stocking became increasingly inconsistent. Some retailers reduced or eliminated shelf space for Cepacol mouthwash products.
• 2025–2026: Availability remains inconsistent. The product is still manufactured but is not reliably stocked at all retail locations. Online availability varies, with third-party sellers sometimes listing the product at 2-3x the normal retail price of $5.99–$9.99.

Prescribing and Recommendation Implications

While Cepacol Antibacterial Mouthwash is an OTC product and doesn't require a prescription, many dental and medical professionals specifically recommend it to patients. The current availability situation has several clinical implications:

Patient Adherence

When a recommended oral care product becomes difficult to find, patients may:

• Discontinue mouthwash use entirely rather than seek an alternative
• Switch to a non-therapeutic cosmetic mouthwash that lacks antigingivitis efficacy
• Use expired product if they've stockpiled an old supply
• Delay follow-up appointments because they feel they haven't been compliant

Clinical Equivalence of Alternatives

Fortunately, the active ingredient in Cepacol — CPC — is available in multiple other OTC products at therapeutic concentrations:

• Crest Pro-Health: CPC 0.07% — higher concentration, widely available
• Colgate Total: CPC 0.075% — highest OTC CPC concentration
• ACT Advanced Care: CPC-based, available at most retailers
• Store-brand CPC mouthwashes: Available at $3.49–$5.99, therapeutic CPC concentration

The minimum recognized therapeutic concentration for CPC is 0.045%. All of the above products meet or exceed this threshold. From a clinical standpoint, any of these alternatives should provide equivalent or superior antigingivitis and antiplaque efficacy compared to Cepacol's 0.05% CPC formulation.

For patients who require more intensive treatment, Chlorhexidine Gluconate 0.12% oral rinse (Peridex, Paroex) remains available by prescription and provides stronger antimicrobial activity, though with the well-known trade-offs of increased tooth staining and taste alteration.

Current Availability Picture

As of early 2026, the availability of Cepacol Antibacterial Mouthwash can be summarized as follows:

• Retail pharmacy chains (Walgreens, CVS): Carried at some locations; not universally stocked
• Mass retailers (Target, Walmart): Intermittently available; varies by store
• Online (Amazon, retailer websites): Available from both official and third-party sellers; prices range from $6–$25+ per bottle
• Hospital/institutional supply: Generally more reliable availability through medical supply channels
• Independent pharmacies: May be able to special-order through distributors

Providers can direct patients to Medfinder for Providers to help locate Cepacol and other products in real time.

Cost and Access Considerations

Because Cepacol Antibacterial Mouthwash is an OTC product:

• Insurance does not cover it — no prior authorization or step therapy applies
• No patient assistance programs exist specifically for this product
• Normal retail cost is $5.99–$9.99 for a 24 fl oz bottle
• Third-party seller markups can push prices to $15–$25+ per bottle
• CPC alternative products are generally comparable or less expensive ($3.49–$9.00)

For patients experiencing financial barriers to oral care products, directing them to store-brand CPC mouthwashes ($3.49–$5.99) provides a cost-effective clinically equivalent option. For more strategies, see our provider guide on helping patients save money on Cepacol Antibacterial Mouthwash.

Tools and Resources for Providers

Several resources can help you assist patients navigating the Cepacol availability challenge:

• Medfinder for Providers: Real-time product availability search tool that checks multiple retailers
• DailyMed (NIH): Full drug facts and labeling for Cepacol Antibacterial Mouthwash (NDC 63824-790)
• Patient handout recommendation: Consider creating a list of approved CPC alternatives your patients can choose from if Cepacol is unavailable

You may also want to review the patient-facing resources we've published, including articles on alternatives to Cepacol and finding Cepacol in stock, which you can share with patients.

Looking Ahead

There is no indication from RB Health (US) LLC that Cepacol Antibacterial Multi-Protection Mouthwash will be discontinued entirely. The product continues to be manufactured and its DailyMed labeling was revised as recently as December 2025. However, retail availability is unlikely to return to pre-2020 levels in the near term given the competitive dynamics of the mouthwash category.

Providers should consider proactively updating their recommendation lists to include CPC alternatives alongside Cepacol. This ensures patients have fallback options and don't interrupt their oral hygiene routines when a specific product is unavailable.

Final Thoughts

The Cepacol Antibacterial Mouthwash availability situation represents a growing trend in consumer health: brand-specific product recommendations may need to evolve toward ingredient-based recommendations. By advising patients to look for "any mouthwash containing Cetylpyridinium Chloride at 0.05% or higher," providers can ensure continuity of care regardless of brand availability.

Stay up to date on product availability through Medfinder for Providers. For additional clinical resources, review our articles on Cepacol's mechanism of action, drug interactions, and the provider's guide to helping patients find Cepacol in stock.